EU/3/16/1672: Orphan designation for the treatment of diffuse large B-cell lymphoma

3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride

Table of contents


On 27 June 2016, orphan designation (EU/3/16/1672) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride (also known as CC-122) for the treatment of diffuse large B-cell lymphoma.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in January 2019.

Key facts

Active substance
3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride
Intended use
Treatment of diffuse large B-cell lymphoma
Orphan designation status
EU designation number
Date of designation

Celgene Europe B.V.
Winthontlaan 6 N
3526 KV Utrecht
The Netherlands
Tel. +31 30 284 4547

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating